At least three analysts said the drugmaker's quarterly revenue beat was driven by Revlimid instead of newer drugs. Sales of Revlimid fell 5% to $1.67 billion, but beat estimates of $1.30 billion.

Cardinal Health Inc. <CAH.N> said on Wednesday that its board increased the company's share repurchase plan by $1.5 billion to a total of $4.5 billion.